Advances in the diagnosis and treatment of hepatocellular carcinoma associated with metabolic associated fatty liver disease
10.3760/cma.j.cn501113-20250709-00271
- VernacularTitle:代谢相关脂肪性肝病相关肝细胞癌诊疗进展
- Author:
Hao ZHENG
1
;
Qianqian CHEN
;
Jie LI
Author Information
1. 南京大学医学院附属鼓楼医院感染性疾病科，南京 210008
- Publication Type:Journal Article
- Keywords:
Metabolic associated fatty liver disease;
Hepatocellular carcinoma;
Epidemiology;
Risk factors;
Precision prevention;
Diagnosis;
Therapeutic
- From:
Chinese Journal of Hepatology
2025;33(9):839-846
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease (MAFLD) has become one of the important causes of hepatocellular carcinoma globally, with the prevalence of obesity and metabolic syndrome. Thus, the incidence of MAFLD-associated hepatocellular carcinoma has increased significantly. Currently, more than 1/3 of such patients often have combined metabolic disorders and can directly progress to hepatocellular carcinoma without going through the cirrhosis stage, which increases the difficulty of early-stage clinical screening, diagnosis and treatment and greatly increases the global disease burden. This paper describes the epidemiological trends and clinical characteristics of MAFLD-associated hepatocellular carcinoma, explores the difficulties in screening and treatment methods, and provides a reference for clinical practice and research.
